Changes in the Revista Medica Electronica 2025

Dear readers and contributors: We begin the year 2025 with the opening of Volume 47 and a new version of the Open Journal System that supports the journal and changes the user interface. However, all the requested data and online work form remains the same.

It is necessary to move to version 3 of Open Journal System for several reasons, from the sustainability and maintenance of the OJS system to security requirements. The adaptation is very fast and you will feel much more comfortable.

Also changes in editorial and section policies are summarized as follows:

In the Results section no bibliographic references are cited, if you need to contrast it will be done in the Discussion.

For research articles, the maximum limit of bibliographic references is raised to 30.

In review articles, all relevant articles used in the discussion should be listed as bibliographic references. If a greater number of references is required, it will be accepted and will be at the decision of the editors.

The format of the review articles is changed, it must include: title, abstract, introduction, method, results, discussion, conclusions (they can be included as a final part of the discussion) and bibliographical references. Optionally, tables and figures may be included. Review articles should be elaborated with the most updated bibliography on the subject and its access in networks.

It is suggested that systematic review articles or those containing meta-analyses should be developed using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) reporting format.

We suggest CONSORT guidelines for clinical trials and CHEERS guidelines for health economic evaluations.

We remind you that Case Presentations are characterized by the discussion of one or more cases of interest, namely:  Clinical syndrome or hereditary or congenital alteration, not previously described; the case is known but its frequency is scarce, so there are problems for its diagnosis; identification of rare clinical manifestations; use of new and more precise diagnostic procedures than those previously referred; use of useful therapeutic procedures not previously described; or use of new drugs not reported with that use in the literature. It is necessary that the above is adequately argued in the document.

It is clarified that accepted papers may require clarifications during the editing process, which will be requested directly by the editor. Failure to respond by the authors may result in the exclusion of the article and its archiving.

We remind you that this journal uses an electronic system for the detection of coincidences as part of its editorial management to guarantee the quality of the publication, which contributes to the prevention of possible plagiarism. Articles with a high level of coincidence are analyzed in depth.

Thank you for your continued interest in our work and trust in our editorial team.

Ph.D. Santiago Almeida Campos.

Director.